You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 5,869,514


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 5,869,514
Title: Terpenoidic derivatives useful as antitumor agents
Abstract:A method of treating tumors in a human or animal by administering thereto a pharmaceutically effective amount of a Sarcodictyin compound selected from Sarcodictyin A, B, C, D, E, and F. Sarcodictyin A has the formula (-)-(4R,4aR,7R,10S,11S,12aR,1Z,5E,8Z)-7,10-Epoxy3,4,4a,7,10,11,12,12a-octa hydro-7-hydroxy-6-(methoxy-carbonyl)-1,10- dimethyl-4-(1-methylethyl)benzo cyclodecen-11-yl(E)-3-(1-Methyl-1H-imidazol-4-yl) acrylate (Sarcodictyin A).
Inventor(s): Battistini; Carlo (Milan, IT), Ciomei; Marina (Pavia, IT), Pietra; Francesco (Lucca, IT), D\'Ambrosio; Michele (Trento, IT), Guerriero; Antonio (Trento, IT)
Assignee: Pharmacia & Upjohn S.p.A. (Milan, IT)
Application Number:08/765,436
Patent Claims:1. A method of enhancing tubulin assembly comprising contacting tubulin with an effective amount of a Sarcodictyin compound selected from the group consisting of

a) (-)-(4R,4aR,7R10S,11S,12aR,1Z,5E,8Z)-7,10-Epoxy3,4,4a,7,10,11,12,12a-octah ydro-7-hydroxy-6-(methoxycarbonyl)-1,10-dimethyl-4-(1-methylethyl)benzo cyclodecen-11-yl(E)-3-(1-Methyl-1H-imidazol-4-yl) acrylate (Sarcodictyin A);

b) (-)-(4R,4aR,7R,10S,11S,12aR,1Z,5E,8Z)-7,10-Epoxy-6(ethoxycarbonyl)-3,4,4a, 7,10,11,12,12a-octahydro-7-hydroxy-1,10-dimethyl-4-(1-methylethyl)benzocycl odecen-11-yl(E)-3-(1-Methyl-1H,imidazol-4-yl)acrylate (Sarcodictyin B);

c) (-)-(3R,4S,4aS,7S,10R,11R,12aS,1Z,5E,8Z)-7,10-Epoxy-3,4,4a,7,10,11,12,12a, octahydro-3,7-dihydroxy-6-(methoxycarbonyl)-1,10-dimethyl-4-(1-methylethyl) benzocyclodecen-11-yl(E)-3-(1-Methyl-1H-imidazol-4-yl)acrylate (Sarcodictyin C);

d) (-)-(3R,4S,4aS,7S,10R,11R,12aS,1Z,5E,8Z)-3-Acetoxy7,10-epoxy-3,4,4a,7,10,1 1,12,12a-octahydro-7-hydroxy-6-(methoxycarbonyl)-1,10-dimethyl-4-(1-methyle thyl)benzocyclodecen-11-yl(E)-3-(1-Methyl-1H-imidazol-4-yl)acrylate (Sarcodictyin D);

e) (+)-(3R,4S,4aS,7S,10R,11R,12aS,1Z,5E,8Z)-7,10-Epoxy-3,4,4a,7,10,11,12,12a- octahydro-3,7-dihydroxy-6-(methoxycarbonyl)-1,10-dimethyl-4-(1-methylethyl) benzocyclodecen-11-yl(Z)-3-(1-Methyl-1H-imidazol-4-yl)acrylate (Sarcodictyin E); and

f) (+)-(1R,4R,4aR,7R,10S,11S,12aR,2Z,5E,8Z)-7,10-Epoxy-1,4,4a,7,10,11,12,12a- octahydro-1,7-dihydroxy-6-(methoxycarbonyl)-1,10-dimethyl-4-(1-methylethyl) benzocyclodecen-11-yl(E)-3-(1-Methyl-1H-imidazol-4-yl)acrylate (Sarcodictyin F).

2. The method of claim 1 wherein said compound is (-)-(4R,4aR,7R,10S,11S,12aR,1Z,5E,8Z)-7,10-Epoxy3,4,4a,7,10,11,12,12a-octa hydro-7-hydroxy-6-(methoxycarbonyl)-1,10-dimethyl-4-(1-methylethyl)benzo cyclodecen-11-yl(E)-3-(1-Methyl-1H-imidazol-4-yl)acrylate (Sarcodictyin A).

3. The method of claim 1, wherein said compound is (-)-(4R,4aR,7R,10S,11S,12aR,1Z,5E,8Z)-7,10-Epoxy-6(ethoxycarbonyl)-3,4,4a, 7,10,11,12,12a-octahydro-7-hydroxy-1,10-dimethyl-4-(1-methylethyl)benzocycl odecen-11-yl(E)-3-(1-Methyl-1H,imidazol-4-yl)acrylate (Sarcodictyin B).

4. The method of claim 1, wherein said compound is (-)-(3R,4S,4aS,7S,10R,11R,12aS,1Z,5E,8Z)-7,10-Epoxy-3,4,4a,7,10,11,12,12a, octahydro-3,7-dihydroxy-6-(methoxycarbonyl)-1,10-dimethyl-4-(1-methylethyl) benzocyclodecen-11-yl(E)-3-(1-Methyl-1H-imidazol-4-yl)acrylate (Sarcodictyin C).

5. The method of claim 1, wherein said compound is (-)-(3R,4S,4aS,7S,10R,11R,12aS,1Z,5E,8Z)-3-Acetoxy-7,10-epoxy-3,4,4a,7,10, 11,12,12a-octahydro-7-dihydroxy-6-(methoxycarbonyl)-1,10-dimethyl-4-(1-meth ylethyl) benzocyclodecen-11-yl(Z)-3-(1-Methyl-1H-imidazol-4-yl)acrylate (Sarcodictyin D).

6. The method of claim 1, wherein said compound is (+)-(3R,4S,4aS,7S,10R,11R,12aS,1Z,5E,8Z)-7,10-Epoxy-3,4,4a,7,10,11,12,12a- octahydro-3,7-dihydroxy-6-(methoxycarbonyl)-1,10-dimethyl-4-(1-methylethyl) benzocyclodecen-11-yl(Z)-3-(1-Methyl-1H-imidazol-4-yl)acrylate (Sarcodictyin E).

7. The method of claim 1, wherein said compound is (+)-(1R,4S,4aR,7S,10R,11R,12aR,2Z,5E,8Z)-7,10-Epoxy-1,4,4a,7,10,11,12,12a- octahydro-1,7-dihydroxy-6-(methoxycarbonyl)-1,10-dimethyl-4-(1-methylethyl) benzocyclodecen-11-yl(E)-3-(1-Methyl-1H-imidazol-4-yl)acrylate (Sarcodictyin F).

8. A method of treating a tumor in a human or animal being having said tumor comprising administering a Sarcodictyin compound to said human or animal being, wherein said Sarcodictyin is a compound selected from the group consisting of:

a) (-)-(4R,4aR,7R,10S,11S,12aR,1Z,5E,8Z)-7,10-Epoxy3,4,4a,7,10,11,12,12a-octa hydro-7-hydroxy-6-(methoxy-carbonyl)-1,10-dimethyl-4-(1-methylethyl)benzocy clodecen-11-yl(E)-3-(1-Methyl-1H-imidazol-4-yl)acrylate (Sarcodictyin A);

b) (-)-(4R,4aR,7R,10S,11S,12aR,1Z,5E,8Z)-7,10-Epoxy-6(ethoxycarbonyl)-3,4,4a, 7,10,11,12,12a-octahydro-7-hydroxy-1,10-dimethyl-4-(1-methylethyl)benzocycl odecen-11-yl(E)-3-(1-Methyl-1H,imidazol-4-yl)acrylate (Sarcodictyin B);

c) (-)-(3R,4S,4aS,7S,10R,11R,12aS,1Z,5E,8Z)-7,10-Epoxy-3,4,4a,7,10,1 1,12,12a,octahydro-3,7-dihydroxy-6-(methoxycarbonyl)-1,10-dimethyl-4-(1-me thylethyl) benzocyclodecen-11-yl(E)-3-(1-Methyl-1H-imidazol-4-yl)acrylate (Sarcodictyin C);

d) (-)-(3R,4S,4aS,7S,10R,11R,12aS,1Z,5E,8Z)-3-Acetoxy-7,10-epoxy-3,4,4a,7,10, 11,12,12a-octahydro-7-hydroxy-6-(methoxycarbonyl)1,10-dimethyl-4-(1-methyle thyl)benzocyclodecen-11-yl(E)-3-(1-Methyl-(1H-imidazol-4yl)acrylate (Sarcodictyin D);

e) (+)-(3R,4S,4aS,7S,10R,11R,12aS,1Z,5E,8Z)-7,10-Epoxy-3,4,4a,7,10,11,12,12a- octahydro-3,7-dihydroxy-6-(methoxycarbonyl)-1,10-dimethyl-4-(1-methylethyl) benzocyclodecen-11-yl(Z)-3-(1-Methyl-1H-imidazol-4-yl)acrylate (Sarcodictyin E); and

f) (+)-(1R,4R,4aR,7R,10S,11S,12aR,2Z,5E,8Z)-7,10-Epoxy-1,4,4a,7,10,11,12,12a- octahydro-1,7-dihydroxy-6-(methoxycarbonyl)-1,10-dimethyl-4-(1-methylethyl) benzocyclodecen-11-yl(E)-3-(1-Methyl-1H-imidazol-4-yl)acrylate (Sarcodictyin F).

9. The method of claim 8, wherein said Sarcodictyin compound is (-)-(4R,4aR,7R,10S,11S,12aR,1Z,5E,8Z)-7,10-Epoxy3,4,4a,7,10,11,12,12a-octa hydro-7-hydroxy-6-(methoxy-carbonyl)-1,10-dimethyl-4-(1-methylethyl) benzo cyclodecen-11-yl(E)-3-(1-Methyl-1H-imidazol-4-yl)acrylate (Sarcodictyin A).

10. The method of claim 8, wherein said Sarcodictyin compound is (-)-(4R,4aR,7R,10S,11S,12aR,1Z,5E,8Z)-7,10-Epoxy-6(ethoxycarbonyl)-3,4,4a, 7,10,11,12,12a-octahydro-7-hydroxy-1,10-dimethyl-4-(1-methylethyl)benzocycl odecen-11-yl (E)-3-(1-Methyl-1H,imidazol-4-yl)acrylate (Sarcodictyin B).

11. The method of claim 8, wherein said Sarcodictyin compound is (-)-(3R,4S,4aS,7S,10R,11R,12aS,1Z,5E,8Z)-7,10-Epoxy-3,4,4a,7,10,11,12,12a, octahydro-3,7-dihydroxy-6-(methoxycarbonyl)-1,10-dimethyl-4-(1-methylethyl) benzocyclodecen-11-yl(E)-3-(1-Methyl-1H-imidazol-4-yl)acrylate (Sarcodictyin C).

12. The method of claim 8, wherein said Sarcodictyin compound is (-)-(3R,4S,4aS,7S,10R,11R,12aS,1Z,5E,8Z)-3-Acetoxy7,10-epoxy-3,4,4a,7,10,1 1,12,12a-octahydro-7-hydroxy-6-(methoxycarbonyl)-1,10-dimethyl-4-(1-methyle thyl) benzocyclodecen-11-yl(E)-3-(1-Methyl-1H-imidazol-4-yl)acrylate (Sarcodictyin D).

13. The method of claim 8, wherein said Sarcodictyin compound is (+)-(3R,4S,4aS,7S,10R,11R,12aS,1Z,5E,8Z)-7,10-Epoxy-3,4,4a,7,10,11,12,12a- octahydro-3,7-dihydroxy-6-(methoxycarbonyl)-1,10-dimethyl-4-(1-methylethyl) benzocyclodecen-11-yl(Z)-3-(1-Methyl-1H-imidazol-4-yl)acrylate (Sarcodictyin E).

14. The method of claim 8, wherein said Sarcodictyin is (+)-(1R,4R,4aR,7R,10S,11S,12aR,2Z,5E,8Z)-7,10-Epoxy-1,4,4a,7,10,11,12,12a- octahydro-1,7-dihydroxy-6-(methoxycarbonyl)-1,10-dimethyl-4-(1-methylethyl) benzocyclodecen-11-yl(E)-3-(1-Methyl-1H-imidazol-4-yl)acrylate (Sarcodictyin F).

15. The method of claim 8, wherein said tumor is resistant to a chemotherapeutic agent.

16. The method of claim 15, wherein said chemotherapeutic agent is an anthracycline glycoside.

17. The method of claim 16, wherein said anthracycline glycoside is Doxorubicin.

18. The method of claim 8 which comprises administering a pharmaceutical composition comprising as an active ingredient a chemical compound selected from the group consisting of Sarcodictyin A, Sarcodictyin B, Sarcodictyin C, Sarcodictyin D, Sarcodictyin E and Sarcodictyin F, said composition containing in addition to said active ingredient a non-toxic, pharmaceutically acceptable, inactive substance selected from diluents, lubricants, binding agents, effervescing mixtures, dyestuffs, sweeteners, wetting agents, carriers and thickening agents.

19. A method as set forth in claim 18, wherein said composition is in solid oral form and contains a diluent selected from the group consisting of lactose, dextrose, saccharose, cellulose, corn starch and potato starch.

20. A method as set forth in claim 18, wherein said composition is a liquid suitable for oral administration and is in the form of a syrup, emulsion or suspension.

21. The method of claim 18, wherein said pharmaceutical composition is in the form of a suspension or solution suitable for injection and contains a pharmaceutically acceptable liquid carrier selected from the group consisting of sterile water, olive oil, ethyl oleate and glycols.

22. The method as set forth in claim 18, wherein said composition is in the form of a suppository and contains a carrier selected from the group consisting of cocoa butter, polyethylene glycol, polyoxyethylene sorbitan fatty acid ester surfactant and lecithin.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.